Long-term tralokinumab therapy in moderate to severe atopic dermatitis

被引：0
|
作者：
Lorenz, Judith
机构：
来源：
AKTUELLE DERMATOLOGIE | 2023年 / 49卷 / 03期
关键词：
D O I：
10.1055/a-1974-5392
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：91 / 91
页数：1
相关论文
共 50 条
  • [21] Long-term efficacy, safety, and adherence to tralokinumab treatment in moderate-to-severe atopic dermatitis for up to 3 years: Interim readout of ECZTEND, a phase 3, long-term extension trial
    Blauvelt, Andrew
    Lacour, Jean-Philippe
    Toth, Darryl
    Laquer, Vivian
    Beissert, Stefan
    Wollenberg, Andreas
    Herranz, Pedro
    Pink, Andrew
    Peris, Ketty
    Saeki, Hidehisa
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB159 - AB159
  • [22] COVID-19 in tralokinumab-treated patients with moderate-to-severe atopic dermatitis: case series from the ECZTEND long-term extension trial
    Blauvelt, A.
    Pink, A.
    Worm, M.
    Langley, R.
    Costanzo, A.
    Gjerum, L.
    Jorgensen, E.
    Corriveau, J.
    Guttman-Yassky, E.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (03) : E109 - E110
  • [23] Tralokinumab therapy for moderate-to-severe atopic dermatitis: Clinical outcomes with targeted IL-13 inhibition
    Simpson, Eric L.
    Guttman-Yassky, Emma
    Eichenfield, Lawrence F.
    Boguniewicz, Mark
    Bieber, Thomas
    Schneider, Shannon
    Guana, Adriana
    Silverberg, Jonathan I.
    ALLERGY, 2023, 78 (11) : 2875 - 2891
  • [24] Emerging Role of Atopic Dermatitis Control Tool in Long-Term Monitoring of Patients With Moderate-to-Severe Atopic Dermatitis Treated With Dupilumab
    Cioppa, Vittoria
    Lazzeri, Laura
    Carraro, Andrea
    De Piano, Ernesto
    Falcinelli, Francesca
    Galluzzo, Marco
    Pallotta, Sabatino
    De Pita, Ornella
    Russo, Filomena
    DERMATITIS, 2024, 35
  • [25] BUDGET IMPACT ANALYSIS OF TRALOKINUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS IN THE UK
    Chalmers, K.
    Sawyer, L.
    Sohrt, A.
    Robinson, S.
    Ryttig, L.
    Rinciog, C.
    VALUE IN HEALTH, 2022, 25 (12) : S124 - S124
  • [26] Long-term systemic corticosteroid therapy in severe atopic dermatitis-Benefits of omalizumab
    Santa, C.
    Barreira, P.
    Lopes, I
    ALLERGY, 2018, 73 : 834 - 834
  • [27] Long-term safety and efficacy of tralokinumab in more than 1400 patients with moderate-to-severe atopic dermatitis treated for up to 42 months: an interim analysis of ECZTEND
    Blauvelt, Andrew
    Langley, Richard
    Simpson, Eric
    Warren, Richard B.
    Costanzo, Antonio
    Saeki, Hidehisa
    Fangel, Stine
    Lassota, Nathan
    Carlsson, Anna
    Toth, Darryl
    Tauber, Marie
    Pinter, Andreas
    Ameen, Mahreen
    Reich, Kristian
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 187 (03) : E92 - E93
  • [28] Long-term safety and efficacy of tralokinumab in more than 1400 moderate-to-severe atopic dermatitis patients treated for up to 42 months: An interim analysis of ECZTEND
    Blauvelt, Andrew
    Langley, Richard
    Simpson, Eric
    Warren, Richard B.
    Costanzo, Antonio
    Saeki, Hidehisa
    Toth, Darryl
    Tauber, Marie
    Pinter, Andreas
    Ameen, Mahreen
    Reich, Kristian
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB181 - AB181
  • [29] Long-term application of extracorporeal photochemotherapy in severe atopic dermatitis
    Prinz, B
    Michelsen, S
    Pfeiffer, C
    Plewig, G
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1999, 40 (04) : 577 - 582
  • [30] Tralokinumab for atopic dermatitis: a promising new therapy
    Morra, D. E.
    Drucker, A. M.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 184 (03) : 386 - 387
12345